Mesoblast (ASX: MSB; OTC ADR: MBLTY) receives FDA Clearance for P3 Bone Marrow Transplant Trial
July 7th, 2011
No comments
Rapid clearance (within 30 days) validates Mesoblast’s clinical, regulatory, and manufacturing capabilities Read more…
